New Oral PKM2 Modulator Shows Promise for Moderate to Severe Atopic Dermatitis
New pill for eczema shows early promise in small study
Researchers and a biotech company recently reported early positive results for an experimental oral medicine aimed at adults with moderate to severe atopic dermatitis, commonly called eczema. The information comes from a company announcement about a small Phase 1b clinical trial. (Source: Sitryx Therapeutics press release)
Quick summary
A new oral drug, SYX-5219, was tested in 35 adults with moderate to severe atopic dermatitis (AD). The study found that people taking the drug had greater improvements in skin severity and itch compared with people taking a placebo after six weeks of treatment. The company says the medicine was generally safe and well tolerated during the study. These are early, small-scale results and more research is needed to know if the drug works and is safe over the long term. (Source: Sitryx Therapeutics press release)
What the trial looked like
The study was randomized, double-blind, and placebo-controlled, which is a strong design for early research. That means participants were randomly assigned to get either the active drug or a placebo, and neither the participants nor the researchers knew who got which until the study ended.
Thirty-five adults with moderate to severe atopic dermatitis at sites in the United States and Europe took part. Participants were assigned in a 2:1 ratio to receive SYX-5219 or placebo for six weeks, followed by a two-week follow-up period off treatment. The company reports the drug’s blood levels and evidence it engaged its intended target matched what they saw in earlier tests in healthy volunteers. (Source: Sitryx Therapeutics press release)
What the results showed
Compared with placebo, people taking SYX-5219 had measurable improvements that started as early as day 8 and increased over the six weeks.
- Skin severity: The placebo-adjusted change in the total Eczema Area and Severity Index (EASI) at six weeks was about 28%. The EASI is a commonly used score that measures the extent and severity of eczema.
- Itch: The difference in Peak Pruritus Numerical Rating Scale (PP-NRS) itch score versus placebo was roughly 48% at six weeks. PP-NRS is a simple scale people use to rate their worst itch.
- Global assessment: More people on the drug reached at least a 1-point improvement on a validated Investigator Global Assessment (vIGA) over time, meaning clinicians saw visible improvement in some participants.
The company also measured blood markers linked to allergic inflammation. They reported decreases in several eczema-related biomarkers, including CCL-17/TARC and CCL-11/eotaxin, and exploratory drops in interleukin-13 (IL-13) and immunoglobulin E (IgE). Participants with asthma appeared to show larger biomarker decreases, which the company says could be relevant to studying the drug in other inflammatory diseases. (Source: Sitryx Therapeutics press release)
How this drug is different
SYX-5219 works in a different way from many current eczema medicines. It targets a cellular enzyme called PKM2 (pyruvate kinase M2). PKM2 helps control how cells—especially immune cells—use energy. The idea is that changing immune cell metabolism may reduce inflammation more broadly than blocking a single inflammatory molecule.
The company describes this as a way to alter immune cell activity and potentially help restore balance in the immune system and improve skin barrier function. These ideas are early and based on laboratory and early clinical data. (Source: Sitryx Therapeutics press release)
Safety and limitations
According to the press release, SYX-5219 was safe and well tolerated during the six-week treatment period in this small group. Blood levels and signs that the drug hit its target were similar to earlier healthy-volunteer studies. (Source: Sitryx Therapeutics press release)
Important caution: the study was small and short. Results from a 35-person Phase 1b trial give only preliminary information. Larger and longer studies are needed to understand how well the drug really works, how long benefits last, and what side effects might appear with wider use. The company itself and independent experts note that more research is required. (Source: Sitryx Therapeutics press release)
What this could mean
If later trials confirm these early findings, SYX-5219 could add a new type of oral treatment option for people with moderate to severe atopic dermatitis. Because it acts through a different biological pathway than many current drugs, it might be helpful for people who need alternatives. But that remains speculative until larger studies are done. (Source: Sitryx Therapeutics press release)
Next steps
Sitryx says it is finalizing the plan for a Phase 2 trial of SYX-5219 in adults with moderate to severe atopic dermatitis, with the study expected to start in the first half of 2027. The company also plans to explore the drug in other autoimmune or inflammatory conditions. Full study results are expected to be presented at a scientific meeting and submitted for peer-reviewed publication. (Source: Sitryx Therapeutics press release)
When to see a doctor
If eczema is affecting your sleep, work, or quality of life, or you have worsening redness, pain, signs of infection (like increasing warmth, pus, or fever), see a healthcare provider. Treatment decisions should be discussed with your dermatologist or primary care doctor. They can help you weigh current, approved treatment options while research continues on new medicines like SYX-5219.
If you track changes in your skin, simple photos over time and notes about symptoms can help you and your doctor see if a treatment is working or if the rash is changing.
Disclaimer
This article summarizes information reported by the company Sitryx Therapeutics about an early-stage clinical trial. It does not provide medical advice. New treatments must go through larger, independent studies before doctors can recommend them. Talk to your healthcare provider about any questions about treatment for atopic dermatitis.
Sources
- Sitryx Therapeutics. Sitryx reports positive Phase 1b results for first-in-class oral PKM2 modulator SYX-5219 in patients with moderate to severe atopic dermatitis. Published October 13, 2026. Accessed October 13, 2026.
- First-in-class oral PKM2 modulator SYX-5219 Phase 1a trial data to be presented at SID 2026. Published May 13, 2026. Accessed October 13, 2026.